After India, Now Indonesia Introduces Patent Licenses For Generic Versions Of Drugs

As we noted a couple of weeks ago, when we wrote about India's moves to issue compulsory licences for the production of generic versions of expensive, patented drugs, the big fear for Western pharmaceutical companies was that other countries might follow suit. It looks like that's happening in Indonesia, where the country's president has signed a decree authorizing low-cost versions of key HIV drugs: 

On Techdirt.

OA and Collectivisation

PLoS Medicine has put together a timely collection of some of its articles on HIV infection and AIDS. Nothing remarkable in that, you might say. But in principle it could have put together a collection of such articles drawing on other open access titles too.

Indeed, I predict this kind of collectivisation will become increasingly popular and important as OA journals gain in popularity. Because this kind of meta-publishing is only really possible in an OA world: traditional publishers would usually rather pull their own heads off rather than allow other rivals to use their texts.

Of course, you might point out that these same publishers will be able to include OA materials in their own collections, whereas PLoS, say, won't be able to draw on commercial titles. But that's fine: it would be an implicit recognition that OA journals are the equals of traditional titles, and would provide buckets of free publicity.

That's the great thing about openness: even freeloaders help the cause, whether they mean to or not. (Via Open Access News.)

Bill Gates Wants to Share "Openly"

It looks like Bill Gates is one step closer to getting it. According to this press release from his foundation, regarding a major research grant to create a series of research consortia to accelerate HIV vaccine development:

These consortia will be linked to five central laboratories and data analysis facilities, enabling investigators to openly share data and compare results, and allowing the most promising vaccine approaches to be quickly prioritized for further development.

...

As a condition for receiving funding, the newly-funded vaccine discovery consortia have agreed to use the central facilities to test vaccine candidates, share information with other investigators, and compare results using standardized benchmarks.

In other words, Gates is demanding open data sharing, and maybe open access too (it's not clear yet, as Peter Suber notes).

But this is a slippery slope, Bill: once you accept the inherent efficiency of sharing data "openly", as the press release emphasises, it's only a short conceptual leap before you find yourself accepting and then encouraging the other ways of sharing stuff "openly"....